Kidney failure creates an unusual internal environment. As renal clearance declines, nitrogenous waste accumulates and changes the chemistry of the gut lumen. Protein-bound toxins such as indoxyl sulfate, p-cresyl sulfate and trimethylamine N-oxide can reach concentrations 10 to 50 times those in healthy controls, according to the review. These compounds are not simply passengers carried by the blood. Indoxyl sulfate activates the aryl hydrocarbon receptor and promotes oxidative stress, while microbial metabolism of tryptophan and tyrosine supplies additional precursors for toxin production. The resulting chemical environment favors pathobionts and disadvantages commensal organisms, including short-chain-fatty-acid producers such as Faecalibacterium and Roseburia.

That shift has structural consequences for the intestine. Butyrate normally supplies energy to colon cells and signals through receptors involved in metabolic and immune regulation. As butyrate-producing bacteria decline, epithelial integrity and anti-inflammatory signaling may weaken. Uremic toxins can also disturb tight-junction proteins, including occludin, claudin-1 and zonula occludens-1. The resulting permeability permits lipopolysaccharide and other microbial products to enter the circulation. Studies summarized in the review link this endotoxemia with higher C-reactive protein and interleukin-6, lower residual kidney function and the low-grade inflammation that characterizes maintenance dialysis. Metabolomic studies also report depleted short-chain fatty acids and altered tryptophan and bile-acid pathways, although most comparisons remain observational.

Immune dysfunction follows two apparently contradictory directions. Pattern-recognition receptors including Toll-like receptor 4, NOD2, NLRP3 and RIG-I respond to microbial products by activating nuclear factor-kappa B and mitogen-activated protein kinase signaling, increasing inflammatory cytokines such as interleukin-6, tumor necrosis factor alpha and interleukin-1 beta. At the same time, uremia impairs neutrophil phagocytosis, monocyte oxidative burst, dendritic-cell antigen presentation and aspects of antibody defense. Altered T-cell and monocyte populations, expansion of myeloid-derived suppressor cells and exhausted T-cell markers have also been described. The result is a state resembling “immunological paralysis”: persistent immune activation alongside reduced capacity to contain infection. The cellular evidence is less extensive than the cytokine evidence and still needs systematic characterization in dialysis-specific cohorts.

Nutrition and muscle are woven into the same feedback system. Protein-energy wasting combines loss of muscle and other body stores with inadequate energy availability. The review reports that muscle mass declines two to three times faster in kidney disease than during normal aging and that malnutrition affects an estimated 18% to 75% of dialysis populations, depending on how it is defined. Inflammation can suppress appetite, activate the ubiquitin-proteasome system and alter myostatin, insulin-like growth factor and JAK–STAT signaling. Restrictive diets may reduce potassium and phosphorus but also limit fiber diversity and the substrates required by saccharolytic bacteria. Evidence connecting dysbiosis to sarcopenia is still mainly cross-sectional or mechanistic: it cannot yet establish whether microbial change causes muscle loss, follows malnutrition and inactivity, or shares inflammation as an upstream driver.

Hemodialysis and peritoneal dialysis place different kinds of stress on this network. Hemodialysis produces rapid fluctuations in toxins and fluid, and rapid ultrafiltration can contribute to intradialytic hypotension and myocardial stunning. Blood repeatedly contacts artificial membranes, activating complement and circulating leukocytes. The review reports more pronounced depletion of butyrate-producing organisms, enrichment of Proteobacteria and Fusobacteria, and generally greater endotoxemia. Peritoneal dialysis is continuous and often preserves residual kidney function and hemodynamic stability for longer, but continuous absorption of glucose adds calories and can worsen insulin resistance, dyslipidemia and adiposity. Glucose degradation products and advanced glycation end-products promote peritoneal inflammation, fibrosis, neoangiogenesis and eventual ultrafiltration failure. Its microbial profile includes amplification of Enterobacteriaceae and depletion of Bifidobacterium and Lactobacillus, though the peritoneal literature is smaller and more vulnerable to confounding by diet, shared environments, medications and other illnesses.

Multi-omics methods offer a way to examine these systems together. Metagenomics and metatranscriptomics characterize microbial genes and active pathways, while metabolomics measures circulating and fecal metabolites, and proteomics, lipidomics and single-cell transcriptomics can characterize immune states. Network analysis and supervised machine learning may detect coordinated signatures that single-domain tests miss. One case-control CKD study cited in the review found that gut microbial functional profiles, including carbohydrate-active enzyme genes, predicted early disease more accurately than serum-metabolite or immune-cell models alone and correlated with circulating amino acids and immune-cell clusters. Such findings demonstrate analytical promise, not a validated patient-classification system. The proposed MIN Index would combine 16S sequencing or metagenomics, multiplex immune assays, biochemical measurements, body composition, functional testing and dietary assessment, with modality-specific weights estimated from outcomes such as infection, hospitalization, cardiovascular events, technique failure and mortality.

Developing that framework would require evidence rather than conceptual polish. The authors suggest a derivation cohort of at least 300 to 500 hemodialysis and peritoneal dialysis patients followed for 12 to 24 months, followed by external validation in a separate population. Sampling would need to cover diet, diabetes, residual kidney function, antibiotics, iron, phosphate binders, proton-pump inhibitors and other medications that can alter microbial communities. Because high-dimensional data invite overfitting, weights derived in one cohort would have to be tested without refitting in another. The index would also have to demonstrate added value over cheaper measures such as the Malnutrition–Inflammation Score, albumin or C-reactive protein, using outcomes that patients experience rather than biomarker changes alone. Its inputs would need to be collected within a defined window, and the test–retest stability of repeated microbiome measurements would need to be established because diet, infection and antibiotics can alter gut composition within days.

Therapeutic ideas remain largely ahead of clinical proof. Fiber-rich and plant-based diets may support short-chain-fatty-acid production, but potassium and phosphorus restrictions complicate implementation, especially in regions where vegetarian diets are already common. Probiotic and prebiotic trials have reported modest improvements in toxins, bowel function or inflammatory markers, generally in small cohorts without demonstration of fewer infections, hospitalizations or deaths. Fecal microbiota transplantation improved kidney and inflammatory measures in a rat model and has early human evidence outside dialysis, but transmission risks, donor screening, uncertain durability and the uremic environment complicate use in frail patients. Omega-3 fatty acids and polyphenols may influence inflammatory pathways, but clinical results are inconsistent. Advanced high-volume hemodiafiltration improves middle-molecule clearance and has produced favorable mortality results in one trial, yet its direct effects on the gut axis remain unmeasured. The review consequently supports carefully monitored research rather than routine use of an unvalidated index or unproven microbiome-based treatment.

Closing the gap will depend on larger, more diverse and longer studies. Most available evidence comes from small, single-center or cross-sectional investigations, often in Western populations, while healthcare access, diet, genetics, environmental exposure and medication use differ markedly across regions. Standardized stool collection, sequencing, bioinformatics and metadata reporting are needed so results can be pooled; common repositories and international consortia could make that possible. Longitudinal cohorts beginning before dialysis could establish whether dysbiosis precedes or follows uremia, infection and malnutrition, while randomized trials of combination interventions could test whether altering several linked domains is more effective than targeting one. The central proposal is therefore not that a single score can immediately guide dialysis care, but that dialysis outcomes may become more predictable if researchers model the gut, immune system, nutrition and residual kidney function as the interacting system they are. The MIN Index offers a structured hypothesis for that work, with its clinical value still to be demonstrated.

Subject of Research: Kidney–gut–immune–nutrition interactions and risk stratification in hemodialysis and peritoneal dialysis

Article Title: Beyond solute clearance: the kidney–gut–immune–nutrition axis in hemodialysis and peritoneal dialysis and a proposed framework for integrated risk stratification

Article References: Rawat, A., Prasad, N., Rawat, P., Ahmed, S., Kumar, B., Singh, A., Nayak, T., & Kushwaha, R. S. (2026). Beyond solute clearance: the kidney–gut–immune–nutrition axis in hemodialysis and peritoneal dialysis and a proposed framework for integrated risk stratification. Frontiers in Nutrition, 13, Article 1931760. https://doi.org/10.3389/fnut.2026.1931760

Image Credits: AI Generated

DOI: 10.3389/fnut.2026.1931760

Keywords: dialysis, gut microbiome, uremic toxins, immune dysregulation, protein-energy wasting, multi-omics, hemodialysis, peritoneal dialysis, risk stratification, clinical nutrition, Beyond, solute

Yu Shenao, Zhou Xinling and Wang Yanru pooled the results using random-effects meta-analyses, with prevalence summarized as a secondary outcome. The analysis estimated the proportion of hemodialysis patients with each condition and examined multivariable-adjusted associations with demographic, clinical, psychological and biochemical factors. Study quality was assessed with the Agency for Healthcare Research and Quality checklist and the Newcastle-Ottawa Scale, while the GRADE approach was used to evaluate certainty. The review protocol was registered with PROSPERO under the identifier CRD420251241385.

Sleep problems were common, but their measured prevalence varied considerably across studies. The pooled estimate for poor sleep quality was 60.6%, with a 95% confidence interval of 56.2% to 64.9% and a 95% prediction interval of 29.2% to 87.7%. For insomnia, the estimate was 42.7%, with a 95% confidence interval of 39.8% to 45.7% and a prediction interval of 34.7% to 51.0%. Restless legs syndrome had a pooled estimate of 23.1%, with a 95% confidence interval of 18.3% to 28.4% and a prediction interval of 4.1% to 51.8%. Sleep apnea was estimated at 47.8%, with a 95% confidence interval of 33.1% to 62.8% and a 95% prediction interval of 1.3% to 97.6%. These wide prediction intervals, particularly for sleep apnea, show that prevalence estimates across individual study settings may differ substantially from the pooled averages.

Several factors were associated with poor sleep quality after the researchers considered other variables. Older age, female sex, lower education, diabetes and depression were each linked to higher odds of poor sleep quality, whereas higher serum albumin was inversely associated with the outcome. Anxiety showed a borderline association that did not reach statistical significance. Among participants whose poor sleep quality was expressed as a continuous PSQI score, older age was associated with greater sleep-disturbance severity, while hemoglobin showed an inverse association. These results describe statistical associations in observational studies; they do not establish that the identified factors cause poor sleep or that changing them would improve sleep.

The review found weaker evidence for restless legs syndrome. Higher serum phosphorus, longer dialysis vintage, a higher intact parathyroid hormone concentration and more frequent exercise each showed borderline associations that were not statistically significant. For insomnia, age was not significantly associated with the condition. Age, sex and hypertension were likewise not significantly associated with sleep apnea. No significant associations were identified for these three conditions in the meta-analysis. Because the evidence for all four sleep outcomes was rated very low in certainty, the findings should be interpreted cautiously. The authors concluded that multiple demographic, clinical, psychological and biochemical factors were associated with poor sleep quality, while several proposed links with restless legs syndrome remained uncertain. The secondary prevalence estimates nevertheless point to sleep disorders as a widespread feature of hemodialysis care, with further research needed to clarify why rates and associated factors vary so widely among patient populations.

Subject of Research: Prevalence and associated factors of sleep disorders among hemodialysis patients

Article Title: Prevalence and associated factors of poor sleep quality, restless legs syndrome, insomnia, and sleep apnea in hemodialysis patients: a systematic review and meta-analysis

Article References: Yu, S., Zhou, X., & Wang, Y. (2026). Prevalence and associated factors of poor sleep quality, restless legs syndrome, insomnia, and sleep apnea in hemodialysis patients: a systematic review and meta-analysis. BMC Public Health. https://doi.org/10.1186/s12889-026-29810-y

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29810-y

Keywords: hemodialysis, poor sleep quality, insomnia, sleep apnea, restless legs syndrome, systematic review, meta-analysis, observational studies, sleep health, Prevalence, associated, factors

The study, conducted by Hatice Oltuluoğlu of the Department of Fundamentals of Nursing at İnönü University’s Nursing Faculty in Malatya, Turkey, examined 123 patients undergoing hemodialysis at two hospitals — a university hospital and a private hospital — between mid-July and the end of August 2023. Rather than drawing a random sample, the researcher aimed to reach the entire eligible population of 145 patients registered in the participating hemodialysis units, ultimately collecting complete data from 123 individuals. The work was approved by an ethics committee (Decision No. 2023/4388) and conducted in line with the Declaration of Helsinki, with verbal informed consent obtained from every participant.

The central question was deceptively simple: does the way patients experience meaning, purpose, and spiritual connection relate to the hope they carry into their treatment? To answer it, the study deployed two well-validated psychometric instruments alongside a standard patient introduction form. Spiritual well-being was measured with the Functional Assessment of Chronic Illness Therapy–Spiritual Well-Being Short Form 12, known as FACIT-Sp-12, a tool widely used in chronic illness research that captures a person’s sense of meaning, peace, and faith in the face of disease. Hope was assessed with the Adult Hope Scale, which measures both the willpower to pursue goals and the perceived pathways for reaching them.

The numbers tell a compelling story. Patients in the study scored an average of 31.34 ± 8.92 on spiritual well-being — a level the author characterizes as moderate but approaching the high-level threshold — and an average of 45.95 ± 8.68 on hope, which falls into the high range. More importantly, the two variables moved together. Pearson correlation analysis revealed a moderate positive association between spiritual well-being and hope, with a correlation coefficient of r = 0.576 and a p-value below 0.001, meaning the relationship is extremely unlikely to be a statistical fluke.

But the study went beyond correlation. Using simple linear regression, Oltuluoğlu tested whether spiritual well-being could actually predict hope scores — and it could, decisively. Spiritual well-being accounted for 33.2 percent of the variance in hope among the hemodialysis patients. In psychological research, where dozens of competing factors — depression, social support, income, symptom burden — typically dilute any single predictor’s explanatory power, one variable explaining a third of the variance in a core psychological resource is a result that demands attention.

The finding fits into a growing international literature. Previous studies have linked spiritual well-being to lower depression and stress in hemodialysis patients in Jordan, to resilience in Turkish dialysis populations, and to better adherence to dietary regimens in Iran. A 2025 latent profile analysis published in Hemodialysis International similarly explored how spiritual well-being shapes hope in this population. What distinguishes the new study is its focus on hope itself — a psychological construct that researchers increasingly view as a protective factor against the hopelessness, suicidal ideation, and depression that have been documented at alarming rates among people with end-stage renal disease.

Why would spirituality matter so much for patients whose kidneys have failed? The mechanisms are likely multifaceted. Chronic illness researchers often describe spiritual well-being as a resource for meaning-making: the ability to reframe suffering within a larger narrative of purpose, faith, or connection to something transcendent. For a patient facing an indefinite future of machine-dependent survival, that reframing capacity may be what allows hope — the belief that goals remain worth pursuing and attainable — to survive the daily reality of fatigue, dietary restrictions, and physical decline. Hope, in turn, has been associated in prior research with better treatment adherence, improved quality of life, and greater psychological resilience.

The clinical implications are concrete. The study’s author argues that integrating spiritual assessment and support into routine nursing care could help strengthen patients’ psychological resilience and perceived hope. In practice, that could mean nurses and clinicians routinely screening for spiritual distress alongside physical symptoms, referring patients to chaplaincy or spiritual counseling services, and acknowledging faith and meaning as legitimate dimensions of care rather than private matters outside the clinical sphere. In Turkey, where the study took place, religious coping is a culturally salient resource, but the underlying principle — that meaning and transcendence are health-relevant — applies across cultural contexts.

The study’s limitations deserve honest framing. As a cross-sectional design, it captures a single moment in time and cannot establish causality: it is equally plausible that hopeful patients find it easier to cultivate spiritual well-being, or that unmeasured third factors — social support, disease duration, comorbidities — drive both. The sample, drawn entirely from two hospitals in one Turkish region, also limits generalizability, and the author notes that causal inferences cannot be established from these data. Data supporting the findings are available from the corresponding author upon request, and the research received no external funding.

Even with those caveats, the study adds weight to an increasingly persuasive argument in psychonephrology and holistic nursing: that the inner life of the dialysis patient is not a luxury but a clinical variable. As hemodialysis continues to sustain a growing global population of patients with kidney failure, interventions that target spiritual well-being — from meaning-centered counseling to simple, structured spiritual assessments at the bedside — may offer a low-cost, culturally adaptable way to protect the one psychological resource that keeps patients engaged with their treatment: hope. The full study is available in Current Psychology, volume 45, article 1630, published online on 19 October 2026.

Subject of Research: The relationship between spiritual well-being and hope in patients undergoing hemodialysis

Article Title: The effect of spiritual well-being on hope in hemodialysis patients: a cross-sectional study

Article References: OLTULUOĞLU, H. (2026). The effect of spiritual well-being on hope in hemodialysis patients: a cross-sectional study. Current Psychology, 45(20), Article 1630. https://doi.org/10.1007/s12144-026-10195-5

Image Credits: AI Generated

DOI: 10.1007/s12144-026-10195-5

Keywords: hemodialysis, spiritual well-being, hope, chronic kidney disease, psychology, nursing, cross-sectional study, FACIT-Sp-12, Adult Hope Scale, psychosocial factors, resilience, Current Psychology

Antineutrophil cytoplasmic antibody-associated vasculitis, abbreviated as AAV, is a systemic autoimmune disease characterized by necrotizing inflammation of small blood vessels. When it strikes both the lungs and the kidneys, clinicians call it pulmonary-renal syndrome, and it ranks among the most lethal presentations of any autoimmune disease. Patients typically develop rapidly progressive glomerulonephritis, in which the kidney’s filtering units are destroyed within days or weeks, alongside pulmonary infiltrates or diffuse alveolar hemorrhage that can suffocate the patient from within. Without aggressive immunosuppressive treatment, mortality is high and kidney failure is often irreversible.

The patient in this case had been in good health until early 2023, with a medical history notable only for kidney stones. In January 2023, routine laboratory tests revealed persistent leukocytosis, an elevated white blood cell count. Over the following months he developed abdominal pain, muscle and joint aches, low-grade fever, fatigue, and swelling of the lower limbs. Multiple courses of empirical antibiotics were administered without any improvement, a pattern that should raise suspicion of a non-infectious cause. His condition then deteriorated dramatically: urine output fell to oliguria and progressed to complete anuria, accompanied by laboratory evidence of severe systemic inflammation.

On admission to the Department of Nephrology at St. George University Hospital in Plovdiv in May 2023, the man was in poor general condition, with arterial hypertension, peripheral edema, pallor, pulmonary congestion, and clinical signs of fluid overload. Laboratory investigations revealed extreme leukocytosis reaching 41 × 10⁹ per liter, thrombocytosis up to 850 × 10⁹ per liter, markedly elevated inflammatory markers, severe acute kidney injury, electrolyte disturbances, and hypoalbuminemia. Serum creatinine, a key marker of kidney failure, reached 700 µmol/L, while potassium climbed to 6.6 mmol/L, a level that threatens fatal cardiac arrhythmia.

Immunological testing provided the diagnostic turning point. The patient tested positive for proteinase 3-ANCA with a cytoplasmic staining pattern, the immunological signature of this form of vasculitis. Critically, antibodies against the glomerular basement membrane were negative, ruling out Goodpasture’s disease, and microbiological cultures showed no infection. Computed tomography of the chest and abdomen revealed bilateral pulmonary infiltrates, pleural and pericardial effusions, pleural-based pulmonary lesions, and enlarged paraaortic lymph nodes, findings that initially kept both severe infection and malignancy in the differential diagnosis.

A percutaneous kidney biopsy settled the question. Light microscopy showed pauci-immune necrotizing crescentic glomerulonephritis, a pattern in which inflammatory cells form crescent-shaped crescents around the glomeruli while immunofluorescence shows little or no immune complex deposition. This histopathological picture is consistent with PR3-ANCA-associated rapidly progressive glomerulonephritis and, importantly, indicated advanced active disease with an unfavorable prognosis for renal recovery. The extent of crescent formation meant that even with perfect treatment, the kidneys were unlikely to regain function.

Treatment began with the standard induction regimen: high-dose corticosteroids and cyclophosphamide, an alkylating chemotherapy agent that has anchored vasculitis therapy for decades. The patient also received hemodialysis, broad-spectrum antimicrobials including meropenem, vancomycin, and metronidazole, thromboembolic prophylaxis with enoxaparin, and human albumin to correct low blood protein levels. Despite this intensive combination, renal recovery was not achieved, and concerns grew about cumulative cyclophosphamide toxicity, which limits prolonged use particularly in critically ill patients already at high risk of infection.

A multidisciplinary team therefore made the decision to escalate to rituximab, an anti-CD20 monoclonal antibody marketed as MabThera. The pharmaceutical rationale was compelling on several fronts. Rituximab works by selectively depleting CD20-positive B lymphocytes, the cells responsible for producing the ANCA antibodies that drive the inflammatory attack. It has demonstrated efficacy comparable to cyclophosphamide for remission induction, with particular effectiveness in PR3-ANCA-positive disease. Crucially for this dialysis-dependent patient, rituximab is not significantly eliminated through the kidneys and is not effectively removed by hemodialysis, so no dose adjustment was necessary. Before initiating the biologic, the team screened for hepatitis B, hepatitis C, and HIV because of the risk of viral reactivation under immunosuppression.

The outcome demonstrated both the power and the limits of modern therapy. Following rituximab administration, systemic inflammatory activity stabilized and the pulmonary involvement regressed, with no new manifestations outside the kidneys during follow-up. However, renal recovery never occurred, and the patient remained chronically dependent on dialysis, a consequence the authors attribute to the advanced crescentic glomerular injury and the delayed diagnosis. The case underscores a sobering reality: controlling the immune attack cannot always reverse damage already done to organs destroyed before treatment began.

Beyond the individual outcome, the report carries broader lessons for the management of severe vasculitis. Delayed diagnosis and high inflammatory burden are associated with irreversible renal damage and increased mortality, making early recognition of ANCA-associated disease essential when patients present with unexplained kidney failure and lung infiltrates. The authors emphasize that careful pharmaceutical monitoring, including complete blood counts, inflammatory markers, electrolytes, immunoglobulin levels to detect hypogammaglobulinemia, and vigilant surveillance for opportunistic infections, remains essential during biologic immunosuppressive therapy. The successful coordination among nephrologists, clinical pharmacists, pathologists, and intensive care specialists in this case illustrates that multidisciplinary care is not an administrative nicety but a determinant of survival in these complex, rapidly evolving diseases.

Subject of Research: Rituximab therapy for severe PR3-ANCA-associated pulmonary-renal syndrome

Article Title: Rituximab therapy in severe PR3 – ANCA pulmonary–renal syndrome: A clinical and pharmaceutical case report

Article References: Nikolov, D., Nikolov, G., Kitova, L., Kitov, S., Kitova, M.-F., & Mihaylova, A. A. (2026). Rituximab therapy in severe PR3-ANCA pulmonary–renal syndrome: A clinical and pharmaceutical case report. Pharmacia, 73, Article e201634. https://doi.org/10.3897/pharmacia.73.e201634

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e201634

Keywords: rituximab, ANCA-associated vasculitis, pulmonary-renal syndrome, PR3-ANCA, glomerulonephritis, case report, autoimmune disease, kidney failure, hemodialysis, immunosuppression, B-cell depletion, clinical pharmacology

The study matters because comfort is one of the most cited yet least examined concepts in nursing science. Kolcaba’s comfort theory, a widely used framework in the field, treats comfort as a multidimensional state spanning physical ease, psychological peace, social belonging and environmental relief. But the theory’s building blocks were largely derived from Western patient populations, and the researchers suspected that the experience of discomfort and comfort among Chinese patients on maintenance hemodialysis might be shaped by cultural values and beliefs that standard assessment tools never capture. If clinicians cannot see comfort through their patients’ eyes, they cannot deliver the person-centred care that health systems around the world now claim as their goal.

To find out, the team turned to interpretative phenomenological analysis, or IPA, a qualitative method designed to uncover how individuals make sense of their lived experiences. Rather than measuring comfort with rating scales, IPA asks researchers to reconstruct the meaning patients attach to their own suffering and relief. The researchers recruited twenty-one adults receiving maintenance hemodialysis at a national public hospital in China and conducted in-depth, semi-structured interviews with each of them between January and May 2025. Interviews were transcribed and then analysed inductively and iteratively, following the six canonical steps of IPA, with the software NVivo 15 used to organize and code the growing dataset. Reporting followed the Consolidated Criteria for Reporting Qualitative Research, the COREQ checklist that sets transparency standards for interview-based studies, and the project received ethics approval from Xiangya Hospital with written informed consent from every participant.

From those twenty-one narratives, three themes crystallized, and together they sketch an arc from endurance to hope. The first theme, which the authors call putting up with the burdens of disease and hemodialysis, describes discomfort as a layered, self-reinforcing condition. Physical symptoms such as fatigue, pain and the after-effects of dialysis sessions did not sit in isolation; they interacted with and aggravated one another. On top of the physical burden came what the researchers describe as overwhelming psychological crises, a compromised social support system in which relationships frayed under the weight of chronic illness, and a disturbing healthcare environment that patients experienced as a source of stress rather than solace.

That last finding is perhaps the study’s most striking technical result. Across all twenty-one interviews, not a single participant described the healthcare environment as a source of comfort. In comfort theory terms, environmental comfort, the relief that comes from pleasant surroundings, attentive staff and a sense of safety within the care setting, was effectively absent from these patients’ lives. For a hospital-based therapy that patients attend multiple times a week for years, the dialysis unit itself, the very place where treatment happens, registered only as a burden. The authors suggest this points to a systematic gap: the physical and interpersonal environment of dialysis units is rarely designed or evaluated with patient comfort as an explicit outcome.

The second theme, experiencing respite in life with hemodialysis, shifts the picture from suffering to relief. Patients described comfort in concrete, almost tactical terms. Early hemodialysis, meaning earlier initiation of treatment or earlier sessions that brought quicker relief from symptoms, was experienced as comfort because it shortened the window of suffering. Family support emerged as a second pillar, with relatives providing both practical help and emotional anchoring. And in a phrase that captures the social texture of Chinese dialysis wards, patients spoke of fellow patients huddling for warmth, the mutual solidarity that develops among people who share the same chairs, the same schedules and the same fears. Comfort, in other words, was not something patients generated alone; it was co-produced by timely treatment, family and community.

The third theme, seeking a decent life with hemodialysis, reveals what patients are reaching for beyond relief. Their articulated comfort needs fell into four categories: freedom from physical and psychological discomfort, the rebuilding of life meaning, a life-oriented healthcare environment, and access to disease-related information. The desire for information is easy to overlook but technically significant, because it reframes patient education not as an optional courtesy but as a comfort intervention in its own right. Patients who understand their disease and their treatment regimen experience a form of cognitive comfort, a reduction in the anxiety produced by uncertainty. Similarly, the demand for a life-oriented environment suggests that patients want dialysis units that acknowledge them as people with identities, routines and futures, not merely as bodies attached to machines.

Woven through all three themes is the influence of the Chinese sociocultural context, which the authors treat not as background noise but as an active variable. Cultural values around endurance, family obligation and face, the social standing that illness can threaten, may shape how patients interpret their discomfort and what they count as comfort. The phrase putting up with, a direct echo of the Chinese concept of forbearance, implies that many patients experience suffering as something to be borne rather than complained about, which has direct clinical consequences: patients who endure silently may underreport symptoms, delaying interventions. The researchers argue that comfort assessment and care planning must therefore be culturally adapted, not simply translated from instruments developed elsewhere.

The practical implications the authors propose are aimed squarely at nurses, who deliver the overwhelming majority of hands-on dialysis care. Because discomfort in this population is multidimensional, with physical symptoms, psychological crises, social isolation and environmental stressors interacting and aggravating one another, single-target interventions are unlikely to succeed. The study’s findings support comfort-focused nursing assessments that map all four dimensions of Kolcaba’s framework for each patient, systematic screening for psychological distress alongside symptom management, deliberate cultivation of peer support structures that formalize the huddling-for-warmth effect, environmental redesign of dialysis units to make them sources of comfort rather than stress, and structured, accessible patient education that satisfies the documented hunger for disease-related information.

What makes this study resonate beyond nephrology is its methodological honesty and its universal message. By listening rather than measuring, the researchers surfaced needs that standardized comfort questionnaires would likely have missed, including the rebuilding of life meaning and the desire for dignity and some control over daily life. The authors conclude that Chinese maintenance hemodialysis patients experience multidimensional discomfort as a burden of everyday life, find comfort through treatment and the support of others, and aspire to live with dignity, meaning and agency. In a world where aging populations and rising rates of diabetes and hypertension are steadily expanding the dialysis population, that conclusion reads less like a local finding and more like a warning for every health system: keeping patients alive is the floor of care, and the ceiling is a life that still feels worth living.

Subject of Research: Comfort experiences and needs of maintenance hemodialysis patients explored through interpretative phenomenological analysis to inform person-centred nursing care

Article Title: The comfort experiences and needs of maintenance hemodialysis patients: a qualitative study to inform person-centred health services

Article References: Huang, Y., Yan, F., Wang, J., Xiao, J., Wiley, J. A., Zhou, J., Adigawe, T., & Sun, M. (2026). The comfort experiences and needs of maintenance hemodialysis patients: a qualitative study to inform person-centred health services. BMC Nursing. https://doi.org/10.1186/s12912-026-05536-5

Image Credits: AI Generated

DOI: 10.1186/s12912-026-05536-5

Keywords: hemodialysis, comfort, discomfort, qualitative research, interpretative phenomenological analysis, person-centred care, nursing, Kolcaba's comfort theory, kidney disease, patient experience, China, quality of life

The study, led by researchers at Qassim University in collaboration with the hospital’s hemodialysis and peritoneal dialysis center, set out to answer a deceptively simple question. Physical function is widely recognized as a key indicator of health status and quality of life among dialysis patients, yet evidence on its prevalence and determinants in Saudi Arabia, particularly in the Qassim region, has remained scarce. Without locally generated data, clinicians have had limited ability to identify which patients are at greatest risk of functional decline or to design culturally appropriate rehabilitation programs.

To fill that gap, the team conducted a hospital-based analytical cross-sectional study over a 16-month period, with participant recruitment and data collection spanning four consecutive months from October 2025 to January 2026. Eligible participants were adults aged 18 or older who had been on maintenance hemodialysis for at least three months, were clinically stable, and could provide written informed consent. The researchers excluded patients with acute dialysis-related complications requiring emergency management, severe cognitive impairment, diagnosed psychiatric disorders, or unrelated medical conditions that could substantially impair physical function, such as recent stroke, major trauma, or limb amputation.

The sampling process was meticulous. Using G*Power statistical software, the team calculated a minimum required sample of 118 participants for multiple regression analysis, assuming a medium effect size, a significance level of 0.05, and 80 percent statistical power. In practice, 130 eligible patients were approached, five declined, 12 participated in a pilot study and were excluded from the final analysis, and three withdrew, leaving a final analytical sample of 110. Data were collected through a structured electronic questionnaire distributed via QR code during scheduled dialysis sessions, with trained research assistants providing standardized assistance to participants who had difficulty completing the survey because of advanced age, limited literacy, or visual impairment.

The questionnaire comprised three validated sections. The first captured sociodemographic and clinical characteristics, including age, gender, education, marital status, dialysis duration, and comorbidities. The second was a 40-item Physical Function Questionnaire assessing mobility, self-care, household activities, and physical exercise, scored on a four-point independence scale and classified using a 50-point threshold referenced from prior literature. The third section evaluated anthropometric measurements, laboratory parameters such as serum calcium, iron, ferritin, and albumin, and common dialysis-related symptoms. Both the physical function instrument and the clinical health status section demonstrated good internal consistency, with Cronbach’s alpha coefficients of 0.85 and 0.81 respectively.

The results were striking. The mean age of participants was 56.8 years, with more than a third aged over 60. Most were married, unemployed, and had one or more comorbid conditions. The mean duration of hemodialysis was 4.8 years, and nearly 95 percent underwent three sessions per week. When physical function scores were converted to percentages of the maximum possible score, the mean was just 37.7 percent, well below the 50 percent cutoff. Eighty-one of the 110 participants, or 73.6 percent, were classified as having impaired physical function, while only 29, or 26.4 percent, preserved adequate function.

The pattern of functional limitation was revealing. Most participants remained independent in basic self-care activities: 76.4 percent could use the toilet independently, 75.5 percent could dress themselves, 65.5 percent could walk, and 57.3 percent could bathe without assistance. But independence collapsed when it came to instrumental activities of daily living. Only 9.1 percent could clean floors independently, 5.5 percent could wash clothes manually, 17.3 percent could cook, 22.7 percent could carry objects, and just 7.3 percent could participate in sports or exercise. Conversely, 78.2 percent reported being unable to wash clothes manually, 70.9 percent could not engage in exercise, and 63.6 percent could not cook. This gradient, preserved basic self-care alongside profound limitations in more physically demanding tasks, suggests that functional decline in dialysis patients follows a predictable trajectory, eroding higher-capacity activities first.

Participants also reported substantial symptom burdens that likely compound their functional challenges. Fatigue was nearly universal, reported by 93.6 percent of participants after dialysis sessions. Sleep disturbances were widespread: 60.9 percent rarely slept well, 60.9 percent always woke at night feeling anxious or stressed, and 56.4 percent always experienced insomnia. Headache affected 37.3 percent, and more than half rated their current health as good while nearly a third perceived their health as worse than the previous year. These symptoms, alongside pain during physical activity reported always by 31.8 percent of participants, paint a picture of a population caught in a cycle where exhaustion, poor sleep, and discomfort reinforce physical inactivity and further functional decline.

When the researchers examined which characteristics were associated with physical function, age emerged as the dominant factor. A statistically significant association was observed between age group and physical function, with the proportion of impaired participants rising from just 17.2 percent among those aged over 60 who preserved function to 50.6 percent of those over 60 with impairment. No significant associations were found with gender, marital status, educational level, employment status, dialysis duration, dialysis frequency, family history of kidney disease, or comorbidities. Multivariable binary logistic regression confirmed that increasing age remained independently associated with impaired physical function after adjustment for sex, body mass index, dialysis duration, hemoglobin, serum albumin, and comorbidity status, with each additional year of age associated with approximately a 7.7 percent increase in the odds of impairment.

The laboratory findings added a nutritional dimension. Participants with impaired physical function had significantly lower mean serum albumin levels than those with preserved function, 39.2 versus 41.5 grams per liter, a difference that reached statistical significance. Lower albumin may indicate less favorable nutritional or clinical status and greater functional vulnerability, though the cross-sectional design precludes establishing causation. Hemoglobin, serum creatinine, calcium, iron, and ferritin did not differ significantly between the two groups, and elevated ferritin concentrations should be interpreted cautiously as they may reflect both iron stores and the inflammatory milieu common in dialysis patients.

The researchers framed their findings through Lazarus and Folkman’s Stress and Coping Theory, which views chronic illness as a dynamic process in which individuals continuously appraise disease-related demands and mobilize coping resources to adapt. Within this framework, maintenance hemodialysis represents a persistent physiological and psychosocial stressor requiring sustained behavioral, emotional, and physical adaptation. Functional status, in this view, reflects not only the severity of clinical condition but also the balance between treatment-related demands, personal coping resources, social support, and healthcare interventions. The theory provides a nursing perspective for understanding functional decline and supports interventions aimed at strengthening adaptive capacity and preserving independence.

The implications for clinical practice are substantial. The authors argue that routine assessment of physical function should be incorporated into standard dialysis care to facilitate early identification of at-risk patients. Regular evaluation of activities of daily living, mobility, fatigue, and sleep quality may enable healthcare professionals to implement timely, individualized interventions. From a nursing perspective, multidisciplinary strategies incorporating exercise training, nutritional counseling, fatigue management, sleep hygiene education, and psychosocial support should be integrated into routine hemodialysis care. Structured rehabilitation programs and patient education initiatives may enhance self-management, promote physical activity, and reduce functional deterioration, particularly among older patients who face the greatest risk.

The study does carry limitations that temper its conclusions. The cross-sectional design precludes establishing causal relationships, and the single-center setting, convenience sampling, and self-reported assessment of physical function may limit generalizability and introduce recall or reporting bias. Comorbidities were assessed as an overall presence or absence without detailed information on individual conditions, precluding analysis of specific comorbidities such as diabetes. Several potentially relevant determinants, including frailty, sarcopenia, muscle wasting, physical activity levels, depression, and inflammatory biomarkers, were not directly assessed. The high prevalence of post-dialysis fatigue also limited its reliable evaluation as an independent factor. Future multicenter prospective studies with larger and more diverse samples and comprehensive clinical, nutritional, psychosocial, and objective functional assessments are warranted.

Nevertheless, the central message resonates beyond Buraydah. As the global burden of chronic kidney disease continues to rise, resulting in increasing numbers of individuals requiring long-term dialysis, maintaining physical function has become a key therapeutic objective that directly influences patients’ ability to remain independent and achieve better clinical outcomes. Declining physical function has been consistently associated with frailty, reduced quality of life, increased hospitalization, greater dependence on caregivers, and higher mortality among patients with end-stage renal disease. The Buraydah findings, showing that nearly three-quarters of dialysis patients carry substantial functional limitations with age as the only independent marker, underscore the urgency of embedding functional assessment and age-sensitive rehabilitation into comprehensive renal care. For a population whose survival now depends on machines, the study reminds clinicians that preserving the ability to cook a meal, wash clothes, or take a walk may be as vital to quality of life as any laboratory value.

Subject of Research: Prevalence and factors associated with physical function among patients undergoing maintenance hemodialysis in Buraydah, Saudi Arabia: a cross-sectional study

Article Title: Prevalence and factors associated with physical function among patients undergoing maintenance hemodialysis in Buraydah, Saudi Arabia: a cross-sectional study

Article References: Qalawa, S. A. A., AlQassem, W. A., Alomeri, K. M., Alharbi, K. S. A., ALsallom, A. I., Elmansy, F. M., & Elbqry, M. G. (2026). Prevalence and factors associated with physical function among patients undergoing maintenance hemodialysis in Buraydah, Saudi Arabia: a cross-sectional study. Frontiers in Nephrology, 6, Article 1935072. https://doi.org/10.3389/fneph.2026.1935072

Image Credits: AI Generated

DOI: 10.3389/fneph.2026.1935072

Keywords: Prevalence, factors, associated, physical, function, patients, undergoing, maintenance, hemodialysis, Buraydah, Saudi, Arabia

The interleukin-1β pathway occupies a central position in the pathogenesis of acute gouty inflammation. Monosodium urate crystals deposited in joints act as danger signals that activate the inflammasome, a multiprotein intracellular complex that processes pro–interleukin-1β into its mature, secreted form. Once released, interleukin-1β drives the vasodilation, endothelial activation, neutrophil recruitment, and pain sensitization that characterize the excruciatingly painful flare typical of gout. Blocking this single upstream cytokine can therefore interrupt much of the inflammatory cascade at once, which is consistent with the rapid pain relief observed in clinical trials of interleukin-1β inhibitors. Firsekibart, as a fully human IgG4 monoclonal antibody, binds interleukin-1β directly and neutralizes its activity. The fully human design is intended to reduce the risk of immunogenicity-related reactions compared with engineered or partially non-human antibodies, an important consideration given that repeated administration may be needed across a patient’s lifetime of recurrent flares.

The pharmacokinetic behavior of monoclonal antibodies provides important context for interpreting the timing observations in this case. Unlike small-molecule drugs, monoclonal antibodies are large proteins that are not meaningfully removed by conventional hemodialysis, which relies on diffusion and convection across a semipermeable membrane with a molecular weight cutoff far below the roughly 150 kilodalton mass of an intact IgG molecule. Antibodies distributed in the plasma and interstitial compartments are also protected from elimination by cellular catabolism and recycling mechanisms, notably the neonatal Fc receptor, which salvages IgG from lysosomal degradation and contributes to the characteristically long half-lives of this drug class, often measured in weeks. On theoretical grounds, therefore, one would not expect a single hemodialysis session to substantially reduce firsekibart exposure, and the absence of pain rebound after dialysis in this patient is consistent with that expectation. Nevertheless, the authors appropriately emphasize that no pre- or post-dialysis concentration measurements were obtained, so the theoretical argument cannot be converted into demonstrated pharmacokinetic fact from this report alone. Directly measured drug levels before and after dialysis sessions would be needed to confirm that dialysis does not materially alter exposure, and such data would be valuable given the complete absence of dedicated pharmacokinetic information in the product label for this population.

The temporal sequence documented in the case deserves careful reading. Pain relief was recorded six to seven hours after firsekibart administration, which is biologically plausible for an interleukin-1β blockade strategy, since neutralizing the cytokine can produce relatively rapid anti-inflammatory effects. However, the patient had also received tramadol and topical flurbiprofen within the hour preceding the documented improvement, and both agents could plausibly contribute to analgesia on that timescale. Tramadol acts centrally on opioid and monoaminergic pathways and can reduce pain perception within hours of dosing, while topical nonsteroidal anti-inflammatory agents can provide localized symptomatic relief. This overlap of interventions is an almost unavoidable feature of clinical care in a patient in severe pain, but it means that the observed improvement cannot be attributed to firsekibart with confidence. The authors’ transparent acknowledgment of this confounding is a strength of the report, and it illustrates a general principle in single-patient observations: temporality is necessary but not sufficient for causal inference, and co-administered therapies must always be considered as alternative explanations.

Equally instructive is what happened over the subsequent weeks. No gout flare recurred through the thirty-five-day follow-up window, which is encouraging given that the patient had experienced flares roughly monthly before this hospitalization. However, the follow-up period was not event-free. The patient developed biliary symptoms, plausibly related to his known gallstones, and a febrile episode with suspected catheter-related bloodstream infection. Both events had plausible alternative explanations independent of firsekibart, but their occurrence underscores a genuine safety consideration for the entire class of interleukin-1β inhibitors. Interleukin-1β is a key component of innate immune defense, and pharmacological blockade of the pathway has been associated with increased susceptibility to infections in other therapeutic contexts. A patient on maintenance hemodialysis is already at elevated infection risk through vascular access, uremia-related immune dysfunction, and recent intensive care admission with invasive devices and broad-spectrum antimicrobial exposure. Disentangling the contribution of cytokine blockade from these background risks in a single patient is essentially impossible, and the authors correctly characterized the relationships as uncertain.

The broader evidence landscape for interleukin-1–directed therapy in gout provides useful perspective on where this case fits. Inhibitors of the interleukin-1 pathway, including agents that block interleukin-1β directly and others that antagonize the interleukin-1 receptor, have been studied in acute gout for well over a decade, with randomized trials demonstrating rapid pain relief in patients for whom conventional therapy was unsuitable, contraindicated, or ineffective. Clinical guidance documents in rheumatology have acknowledged interleukin-1 inhibition as an option for flares in which first-line agents cannot be used. What has been persistently missing is evidence in the dialysis population, because pivotal trials commonly exclude patients with advanced kidney disease out of concern for safety, pharmacokinetic uncertainty, and confounding comorbidity. The consequence is a circular problem: dialysis patients are excluded from trials because data are lacking, and data remain lacking because dialysis patients are excluded. Case reports such as this one, while individually weak in inferential terms, are often the first signals that accumulate to justify formal pharmacokinetic and safety studies in excluded populations.

Several methodological limitations inherent to this report merit emphasis for readers weighing its implications. The retrospective design means that the timing of assessments, including visual analogue scale pain scoring, was dictated by routine clinical care rather than a prespecified protocol, introducing potential measurement imprecision. The absence of serum urate trajectory data during the flare limits interpretation, since the reported value of 506 micromoles per liter reflects the inflammatory and renal context rather than a controlled baseline. The lack of histopathology for the previously excised elbow lesion leaves the diagnosis of gouty tophus based on imaging and clinical pattern rather than tissue confirmation, although the polyarticular presentation, recurrent flare history, and markedly elevated uric acid make the clinical diagnosis reasonable. Finally, the co-administration of multiple analgesic and anti-inflammatory agents around the time of firsekibart dosing, as noted above, prevents isolation of the drug’s specific contribution to symptom resolution.

For clinicians, the practical takeaway is not that firsekibart is established therapy for gout in hemodialysis patients, but that this case documents a real-world instance of its use in exactly the kind of multimorbid patient in whom conventional options are constrained. The observations—apparent early pain relief, no rebound after dialysis, no immediate hypersensitivity reaction, and no flare recurrence over five weeks—are consistent with theoretical expectations for an IgG4 antibody in this setting, but they are observations, not proof. Future studies that directly measure firsekibart concentrations across dialysis sessions, systematically capture infection and other adverse events, and compare interleukin-1β blockade against optimized conventional regimens in dialysis patients would convert this anecdote into actionable evidence. Until such data exist, decisions in comparable patients will continue to rest on individualized risk-benefit assessment, multidisciplinary judgment, and the careful documentation of outcomes that reports like this one provide.

Subject of Research: Use of firsekibart for acute gouty arthritis in a maintenance hemodialysis patient with multiple high-risk comorbidities: a case report

Article Title: Use of firsekibart for acute gouty arthritis in a maintenance hemodialysis patient with multiple high-risk comorbidities: a case report

Article References: Chen, J., Tong, R., Shen, M., Zhang, W., & Huang, Y. (2026). Use of firsekibart for acute gouty arthritis in a maintenance hemodialysis patient with multiple high-risk comorbidities: a case report. Frontiers in Pharmacology, 17, Article 1928098. https://doi.org/10.3389/fphar.2026.1928098

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1928098

Keywords: firsekibart, acute, gouty, arthritis, maintenance, hemodialysis, patient, multiple, high-risk, comorbidities, case, report

The research, conducted at Hospital Alberto Barton Thompson in Callao and published in Frontiers in Nephrology, set out to answer a deceptively simple question: when a bedside exam, a bioimpedance scan, and a lung ultrasound are all performed on the same patient on the same morning, do they agree? The answer, quantified with statistical rigor, was largely no. The three methods captured overlapping but partially distinct slices of a patient’s true fluid status, and the disagreements were not random noise but appeared to reflect genuinely different physiology.

The technical centerpiece of the study is the B-line, a vertical, laser-like reverberation artifact that streaks down an ultrasound image from the pleural line and moves in synchrony with lung sliding. B-lines increase when fluid accumulates in the interlobular septa and alveoli of the lung, making their count a practical surrogate for extravascular lung water. The team used an abbreviated six-zone protocol, scanning two intercostal spaces along the midclavicular line and one along the midaxillary line on each side, a compromise that previous validation work has shown performs comparably to the traditional 28-zone survey while cutting acquisition time dramatically. Two formally trained nephrologists performed all scans with a handheld Butterfly iQ+ device, blinded to every other clinical and bioimpedance finding, and adjudicated disagreements by consensus.

Alongside the ultrasound, each patient underwent whole-body bioimpedance spectroscopy using a Fresenius Body Composition Monitor, which estimates how many liters of excess extracellular fluid a person carries relative to their normohydrated state. The investigators also performed a standardized clinical examination, recording dyspnea, crackles, peripheral edema, blood pressure, and interdialytic weight gain, and defined clinical euvolemia as the absence of all congestion signs. All measurements were taken immediately before the same midweek dialysis session, eliminating the temporal drift that has muddied earlier comparisons.

The headline result is striking. Of the 49 patients judged clinically euvolemic, 27, or 55.1 percent, had three or more B-lines on lung ultrasound, meeting the prespecified definition of subclinical pulmonary congestion. That subgroup alone constituted 23.3 percent of the entire cohort. In other words, nearly one in four dialysis patients in this study was walking around with objectively wet lungs despite a clean physical examination, no edema, and no crackles. Overall, 70.7 percent of participants had ultrasound-defined pulmonary congestion, and 41.4 percent had moderate-to-severe congestion with ten or more B-lines.

Agreement statistics drove the point home. Clinical examination showed only fair agreement with lung ultrasound at the three-B-line threshold, with a Cohen’s kappa of 0.28, improving to a still-modest 0.41 at the ten-B-line cutoff. Agreement between lung ultrasound and bioimpedance-defined overhydration was slight, at kappa 0.16, and the ultrasound agreed barely at all with elevated interdialytic weight gain, at kappa 0.08. Even the two objective technologies, which might naively be expected to converge, classified the same patients differently. The authors argue this physiological discordance is the story itself: fluid overload describes expansion of the body’s extracellular compartment, whereas congestion describes where that fluid actually accumulates and redistributes, and the two do not move in lockstep.

By combining clinical and ultrasound findings, the team carved the cohort into four volume phenotypes. Twenty-two patients were concordantly euvolemic, 55 were concordantly congested, 12 showed clinical signs without ultrasound congestion, and 27 occupied the discordant zone of subclinical pulmonary congestion. The phenotypes sorted cleanly along physiological gradients: concordantly congested patients had the highest weight gain, the greatest bioimpedance overhydration, and the heaviest B-line burden, while concordantly euvolemic patients sat at the bottom of every measure. The subclinical group fell in between, with intermediate overhydration that a stethoscope simply could not see.

Regression analysis sharpened the clinical message. Among euvolemic patients, each additional liter of bioimpedance-derived overhydration was associated with a 24 percent higher prevalence of subclinical pulmonary congestion, while interdialytic weight gain, the traditional dialysis-unit benchmark, lost all statistical significance after adjustment. Male sex was independently associated with a 45 percent lower prevalence of occult congestion. Blood pressure told a similarly bifurcated tale: systolic pressure correlated moderately with systemic overhydration but not with B-lines, whereas diastolic pressure showed only a weak link to lung water. These patterns reinforce the idea that whole-body fluid volume, weight fluctuation, and pulmonary congestion are separable physiological dimensions rather than interchangeable labels.

The findings resonate with a growing international literature. Meta-analyses report pulmonary congestion in roughly one half to two thirds of maintenance hemodialysis patients worldwide, and the landmark LUST study found that pulmonary crackles, the classic auscultatory sign, detected significant congestion with a sensitivity of only about 22 percent. Studies from Asia and Europe have likewise shown that patients deemed normohydrated by bioimpedance frequently carry ultrasound-visible lung water. The Peruvian cohort, notable as one of the first Latin American populations examined with this triple assessment, adds weight to the argument that clinically silent congestion is a reproducible global phenomenon rather than a local artifact.

What the study cannot yet say is whether acting on this hidden information saves lives. Its cross-sectional design precludes causal inference, it came from a single center where most patients dialyzed through central venous catheters, and echocardiography was available for only about half the cohort. The three-B-line threshold for subclinical congestion was prespecified but not universally validated, though sensitivity analyses at five and ten B-lines produced similar patterns. Still, the clinical direction is clear. The authors do not propose replacing the hands and stethoscope of conventional assessment, but they make a strong case for layering lung ultrasound and bioimpedance on top of it when fluid status is uncertain. With randomized trials of ultrasound-guided fluid management already underway, the era in which a wet lung could hide in plain sight on a dialysis chair may soon be ending.

Subject of Research: Discordance among clinical examination, bioimpedance spectroscopy, and lung ultrasound for assessing fluid status and pulmonary congestion in maintenance hemodialysis patients

Article Title: Physiological discordance between clinical examination, bioimpedance spectroscopy, and lung ultrasound in maintenance hemodialysis patients without heart failure

Article References: Benites-Flores, I. R., Rodríguez Revilla, J., Taype-Rondan, A., Fernández-Anticona, L. C., Prado Ramírez, P. A., Seminario Alegre, N., Rodríguez Tudero, C., Moral Berrio, E., Jimenez Mayor, E., Chandu Nanwani, A., & De la Flor, J. C. (2026). Physiological discordance between clinical examination, bioimpedance spectroscopy, and lung ultrasound in maintenance hemodialysis patients without heart failure. Frontiers in Nephrology, 6, Article 2000700. https://doi.org/10.3389/fneph.2026.2000700

Image Credits: AI Generated

DOI: 10.3389/fneph.2026.2000700

Keywords: hemodialysis, lung ultrasound, bioimpedance spectroscopy, pulmonary congestion, B-lines, volume assessment, fluid overload, point-of-care ultrasound, nephrology, subclinical congestion, dry weight, cardiovascular risk

The study team used three non-consecutive 24-hour dietary recalls, a standard technique in which trained interviewers ask participants to reconstruct everything they ate and drank over the previous day. Each participant completed three recalls on days that were not consecutive, which helps smooth out day-to-day variation in eating patterns. The researchers then compared reported intakes of energy, protein, sodium, and phosphorus against the KDOQI recommendations for hemodialysis patients, which specify an energy intake of 30 to 35 kilocalories per kilogram of body weight per day and a protein intake of at least 1.0 gram per kilogram per day. Appetite was assessed separately using the Appetite and Diet Assessment Tool, a validated questionnaire designed to capture the reduced hunger that is common in kidney disease.

The critical methodological innovation was the plausibility screening. Self-reported dietary intake is notoriously unreliable, because people systematically forget snacks, underestimate portion sizes, and sometimes consciously or unconsciously describe what they believe they should be eating. To detect this, the researchers calculated the ratio of each participant’s reported energy intake to their estimated basal metabolic rate, the energy the body burns at complete rest. Ratios that fall far below physiologically expected values signal under-reporting, while unusually high ratios signal over-reporting. Of the 178 participants with complete data, 65.2 percent reported energy intakes in the acceptable range, but 32.0 percent under-reported and 2.8 percent over-reported. In other words, roughly one in three patients gave accounts of their diets that were physiologically implausible.

The raw numbers before screening were already sobering. Only 20 of 176 participants, or 11.4 percent, met the energy target of 30 to 35 kilocalories per kilogram per day, and just 58 participants, or 33.0 percent, met the protein target of at least 1.0 gram per kilogram per day. On its face, this suggested a population facing severe dietary inadequacy, with most patients failing to eat enough to maintain their body mass and muscle stores. For a clinical team, such figures would argue for urgent nutritional supplementation, intensive dietary counseling, and possibly oral nutrition supplements for the majority of the dialysis population.

But when the researchers excluded the implausible reports, the estimates moved in opposite directions depending on the type of target, and this asymmetry is the study’s most important technical contribution. For intake targets, where the goal is to consume enough, adherence rose once under-reporters were removed from the analysis: energy compliance climbed from 11.4 percent to 15.5 percent, and protein compliance jumped from 33.0 percent to 47.4 percent. The logic is straightforward. Under-reporting makes it look as though patients are eating too little, so removing those biased records raises the apparent proportion of patients who actually meet minimum intake goals. Nearly half of plausible reporters were meeting the protein target, a considerably less alarming picture than one in three.

For restriction targets, the pattern reversed. Apparent adherence to the sodium limit fell from 73.6 percent to 65.5 percent after screening, and adherence to the phosphorus limit fell from 88.2 percent to 84.5 percent. Here the bias runs the other way: under-reporting makes it seem as though patients are consuming less sodium and phosphorus than they really are, inflating the apparent success of dietary restriction advice. Once implausible records are excluded, the true scale of excess sodium and phosphorus consumption becomes visible, and it is larger than the raw self-report data suggested. Unscreened self-report therefore simultaneously overstates dietary inadequacy and understates dietary excess, a double distortion that pushes clinical decisions in two wrong directions at once.

One finding stood out as nearly universal: the phosphorus-to-protein ratio exceeded 12 milligrams per gram in all but five participants. This ratio is a measure of dietary quality, because phosphorus in the diet tends to travel with protein, and foods that deliver protein with a heavy phosphorus load are particularly problematic for dialysis patients whose kidneys can no longer excrete the mineral. Elevated phosphorus drives secondary hyperparathyroidism, vascular calcification, and cardiovascular mortality in this population. A ratio above 12 milligrams per gram in virtually the entire cohort indicates that the available protein sources in these patients’ diets, likely dominated by legumes, grains, and processed items rather than phosphorus-lean animal proteins, carry an unfavorable mineral burden regardless of how much protein patients consume.

The appetite findings added a further layer of complexity. Poor appetite, assessed with the Appetite and Diet Assessment Tool, was common, affecting 42.0 percent of participants. Appetite loss is a recognized harbinger of protein-energy wasting in dialysis patients and is often treated as a direct driver of low intake. Yet in this study, poor appetite did not correspond to lower measured intake. Instead, appetite scores were associated with reporting plausibility, with a statistically significant relationship at p equal to 0.024. This suggests that patients who described poor appetite may have been describing their perception of their eating rather than their actual consumption, or that appetite influenced how they reported their diets rather than the diets themselves. For clinicians, this decoupling of subjective appetite from objective intake is a caution against using appetite questionnaires alone to identify patients at nutritional risk.

The clinical implications extend well beyond the four Bangladeshi dialysis units where the data were collected. Resource-limited settings have historically been underrepresented in nutrition research, and this study provides some of the first rigorous evidence on how KDOQI guideline compliance actually looks in South Asian hemodialysis populations, where dietary patterns, food costs, and access to renal dietitians differ substantially from the high-income contexts in which the guidelines were developed. The finding that nearly half of plausible reporters met protein targets, while almost none of the raw data suggested such compliance, demonstrates that screening for plausibility is not a statistical nicety but a decisive step that changes conclusions. Nutrition interventions designed on the basis of unscreened recall data could waste resources addressing a deficiency that is partly an artifact of measurement, while missing the genuine excess of sodium and phosphorus that screening reveals.

The broader lesson is one that nutrition science has been absorbing across many fields: self-reported dietary intake should not be used unfiltered to guide nutritional decisions. The authors’ conclusion applies with particular force to dialysis care, where the difference between eating too little protein and eating too much phosphorus can shape survival over years of treatment. Objective biomarkers, structured plausibility screening, and repeated recalls each add cost and complexity, but this study shows what happens when they are skipped: a population that appears starved of energy and protein may in fact be consuming more than the raw numbers suggest, while quietly exceeding the mineral limits that matter most for cardiovascular health. For the growing global population of dialysis patients, most of whom now live in low- and middle-income countries, closing that measurement gap may be as important as any new drug.

Subject of Research: Dietary intake patterns and KDOQI guideline compliance among hemodialysis patients in Bangladesh, with plausibility screening of self-reported intake

Article Title: Dietary intake patterns and KDOQI guideline compliance among hemodialysis patients in Bangladesh: Gaps, misreporting, and clinical implications

Article References: Akter, F., Rahman, T., Ahmed, S., Ripon, M. S. H., Sultana, M., Sultana, N., & Rashid, H.-U. (2026). Dietary intake patterns and KDOQI guideline compliance among hemodialysis patients in Bangladesh: Gaps, misreporting, and clinical implications. PLOS One, 21(10), e0360654. https://doi.org/10.1371/journal.pone.0360654

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360654

Keywords: hemodialysis, KDOQI guidelines, dietary intake, nutrition, Bangladesh, 24-hour recall, under-reporting, phosphorus-to-protein ratio, protein-energy wasting, appetite assessment, renal dietetics, PLOS One

The research, published in the journal Current Psychology, was conducted by Halise Taşkın Duman, Füsun Uzgör, and Pınar Çiçekoğlu Öztürk of Muğla Sıtkı Koçman University. The team set out to answer a deceptively simple question: what predicts happiness in people undergoing maintenance hemodialysis? Their answer, drawn from 186 patients, is strikingly concrete. Three variables—sleep quality, mental well-being, and psychological resilience—together explained 64.8 percent of the variance in happiness scores, a remarkably large share for research on subjective well-being in any population, let alone one facing the physiological disruptions of kidney failure.

The study used a descriptive and correlational design, relying on four well-validated instruments. Happiness was measured with the Oxford Happiness Questionnaire, sleep quality with the Pittsburgh Sleep Quality Index, mental well-being with the Warwick-Edinburgh Mental Well-Being Scale, and resilience with the Brief Resilience Scale. Each of these tools captures a different dimension of the patient’s inner and outer life: the emotional tone of daily experience, the architecture of the night, the sense of psychological flourishing, and the capacity to bounce back from adversity. By combining them, the researchers built a statistical portrait of what it feels like, and what it takes, to be happy while living on dialysis.

The headline finding concerns sleep. Overall happiness, mental well-being, and resilience in the sample were generally moderate, but sleep quality was poor—and poor sleep was significantly linked to inadequate social support and to the disruption of the sleep-wake cycle caused by dialysis sessions themselves. This is not a trivial side effect. Hemodialysis typically requires patients to attend clinics three times a week, often in the early morning, upending natural circadian rhythms. Add to that the physical discomfort of treatment, symptoms such as itching, and the metabolic disturbances of end-stage kidney disease, and the result is a population in which insomnia and fragmented sleep are common. Previous systematic reviews and meta-analyses have documented high rates of insomnia and poor sleep in chronic kidney disease, and the new study now ties that disturbed sleep directly to the emotional lives of patients.

Statistically, the relationships were clear and consistent. Happiness correlated negatively with sleep quality scores on the Pittsburgh index—meaning that worse sleep, which produces higher scores on this instrument, went hand in hand with lower happiness (r = -0.318, p < 0.01). Happiness correlated positively and strongly with mental well-being (r = 0.764, p < 0.01) and with psychological resilience (r = 0.556, p < 0.01). In the regression model, the three predictors jointly accounted for nearly two-thirds of the differences in happiness between patients (F = 111.746, p < 0.001). The strength of the well-being association in particular suggests that how patients appraise their psychological state matters enormously, but the sleep finding is the one with the most obvious practical implications, because sleep is something clinicians can assess and, in principle, treat.

The study also found that happiness, well-being, and resilience varied significantly with social circumstances. Education level, social support, full-time employment status, changes in family relationships after starting dialysis, and the impact of dialysis sessions on the sleep-wake cycle all shaped psychological outcomes. Patients with more education, jobs, and supportive families fared better. This aligns with a broader body of evidence: meta-analytic work has shown that social support is associated with better sleep, and longitudinal research in hemodialysis populations has linked social and family support to greater psychological resilience. Happiness, in other words, is not manufactured inside the skull alone. It is scaffolded by relationships, routines, and the practical stability that work and education provide.

Why should sleep matter so much for happiness in this population? The authors point to the physiological disruption that dialysis imposes on the sleep-wake cycle, but the mechanisms likely run in both directions. A large meta-analysis of randomized controlled trials has shown that improving sleep quality leads to measurable improvements in mental health, suggesting sleep is not merely a symptom of distress but a causal contributor to it. Poor sleep amplifies pain perception, impairs emotional regulation, and erodes the energy needed to maintain social ties—the very ties that the study found to be protective. For a dialysis patient, a bad night can cascade into a worse day, a skipped social engagement, and a deepening sense of isolation, while better sleep could interrupt that spiral.

Resilience, the capacity to recover from stress, emerged as the second-strongest correlate of happiness. This fits with a growing literature on chronic illness. Studies in patients with diabetes, multiple sclerosis, and rheumatic disease have found that resilience predicts social and professional functioning, and research in Japanese hemodialysis patients has shown that resilience mediates the relationship between family functioning and mental well-being. The Turkish findings extend this picture by showing that resilience operates alongside, not instead of, physiological factors. A patient who sleeps poorly and feels isolated will struggle to be happy no matter how naturally resilient they are; conversely, resilience cannot compensate for a circadian rhythm shattered by three weekly dialysis sessions. The biopsychosocial framework that has gained traction in nephrology—treating kidney disease as a condition of body, mind, and social world simultaneously—appears well supported by these numbers.

The practical message for clinicians is that holistic care is not a slogan but a statistical necessity. If nearly two-thirds of the variation in happiness can be traced to sleep, well-being, and resilience, then nursing interventions that target only the physical aspects of dialysis leave most of the psychological picture untouched. The authors argue for care that combines sleep management with psychosocial support: screening for sleep disorders, adjusting dialysis schedules where possible, involving families, and building programs that strengthen coping skills. Prior interventional studies lend plausibility to this approach. Happiness training programs have reduced depression and anxiety and improved quality of life in hemodialysis patients, and hope-based group therapy has improved general health and happiness. Nonpharmacological sleep interventions are likewise being evaluated for this population.

There are, of course, limits to what a single cross-sectional study of 186 patients in one country can establish. Correlation does not prove causation, and it remains possible that unhappy patients sleep worse rather than the reverse, or that some unmeasured factor—disease severity, comorbid depression, time on dialysis—drives both. The authors also note that the data, containing sensitive clinical and psychosocial information from a vulnerable population, are available only on reasonable request rather than openly. Still, the size of the explained variance is hard to dismiss, and the convergence of these findings with international evidence on sleep, social support, and resilience in kidney disease gives the results considerable weight.

What makes the study resonate beyond nephrology is its implicit theory of happiness under adversity. Happiness, the data suggest, is not the absence of illness but the presence of conditions: restorative sleep, a sense of psychological flourishing, the capacity to recover from setbacks, and a web of people who care. For the 186 patients in this study, and for the millions like them, those conditions are not luxuries. They are, in a very real sense, part of the treatment.

Subject of Research: Predictors of happiness among hemodialysis patients, focusing on sleep quality, mental well-being, and psychological resilience

Article Title: Predictors of happiness in hemodialysis patients: the roles of sleep, mental well-being, and resilience

Article References: Duman, H. T., Uzgör, F., & Öztürk, P. Ç. (2026). Predictors of happiness in hemodialysis patients: the roles of sleep, mental well-being, and resilience. Current Psychology, 45(19), Article 1580. https://doi.org/10.1007/s12144-026-10139-z

Image Credits: AI Generated

DOI: 10.1007/s12144-026-10139-z

Keywords: hemodialysis, happiness, sleep quality, mental well-being, psychological resilience, chronic kidney disease, social support, insomnia, health psychology, quality of life, nursing interventions, Türkiye